Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490009
Status:
COMPLETED
Last Update Posted:
2017-03-30
First Post:
2007-06-20
Brief Title:
Phase 2 Study of Bexxar in RelapsedRefractory DLCL
Sponsor:
Susan Knox
Organization:
Stanford University
Study Overview
Official Title:
Phase 2 Study of Bexxar in RelapsedRefractory Diffuse Large Cell Lymphoma DLCL
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsedrefractory diffuse large cell Non-Hodgkins lymphoma DLCL
Detailed Description:
There is a lack of efficacious treatment options for patients with relapsedrefractory diffuse large cell Non-Hodgkins lymphoma DLCL who are not appropriate candidates for stem cell transplantation DLCL is a relatively radiosensitive disease and patients with DLCL have been reported to respond to anti-CD20 monoclonal antibody MAB therapy Therefore radioimmunotherapy targeting CD20 is a rational and promising therapeutic approach for this patient population
This study evaluated if Bexxar is safe and efficacious for diffuse large cell Non-Hodgkins lymphoma
This study evaluated if Bexxar is safe and efficacious for diffuse large cell Non-Hodgkins lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LYMNHL0019 | OTHER | None | None |
| 30978 | OTHER | Stanford SPO | None |